Overview

Use of Pancreatic Enzymes in Short Bowel Syndrome

Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
Patients with short bowel syndrome have a high mortality rate that is mainly attributed to complications from central lines and long-term intravenous (IV) nutrition. There are few medical therapies to date that improve gut absorption in patients with short bowel syndrome. The primary objective of this study is to evaluate if absorption from the GI tract improves in subjects with short bowel syndrome following therapy with pancreatic enzymes.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborator:
AbbVie